1 Min Read
March 14 (Reuters) - Acasti Pharma Inc:
* ACASTI PHARMA ANNOUNCES FIRST PATIENT RANDOMIZED IN PIVOTAL TRILOGY PHASE 3 PROGRAM OF CAPRE IN SEVERE HYPERTRIGLYCERIDEMIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.